60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
Key Highlights
- ➤60 Degrees partners with USM to evaluate castanospermine in alpha-gal syndrome models
- ➤Company will fund research and retain an option to commercialize resulting intellectual property
- ➤60 Degrees plans to assess botanical approval pathways before prescription-drug development
- ➤USM research will guide development decisions for a potential castanospermine product
- ➤ARAKODA received FDA approval in 2018; company has three active babesiosis trials
WASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM) to assess the therapeutic potential of castanospermine—a naturally occurring iminosugar derived from the Australian Chestnut (Castanospermum australe)—in nonclinical models of alpha-gal syndrome (AGS).
The partnership leverages USM’s established vector biology research expertise and investigator insights into tick-borne disease. Under this agreement, 60 Degrees will underwrite the research and retains an option to commercialize and market any resulting intellectual property.
Get started
Create a free account to read the full story.